Cadrenal Therapeutics (CVKD)

Profile

Full Name

Cadrenal Therapeutics, Inc.

Ticker Symbol

CVKD

Exchange

NASDAQ

Country

United States

IPO

January 20, 2023

Indexes

Not included

Employees

4

Key Details

Price

$15.00(+5.12%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$8.73(+6.03% YoY)

PE ratio

-

Next earnings date

May 30, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Nov 11, 24 HC Wainwright & Co.
Buy
Jun 6, 24 HC Wainwright & Co.
Buy
May 9, 24 HC Wainwright & Co.
Buy
Mar 14, 24 HC Wainwright & Co.
Buy
Dec 18, 23 Noble Capital Markets
Outperform
Nov 20, 23 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for Cadrenal Therapeutics?
  • Does Cadrenal Therapeutics pay dividends?
  • What sector is Cadrenal Therapeutics in?
  • What industry is Cadrenal Therapeutics in?
  • What country is Cadrenal Therapeutics based in?
  • When did Cadrenal Therapeutics go public?
  • Is Cadrenal Therapeutics in the S&P 500?
  • Is Cadrenal Therapeutics in the NASDAQ 100?
  • Is Cadrenal Therapeutics in the Dow Jones?
  • When was Cadrenal Therapeutics's last earnings report?
  • When does Cadrenal Therapeutics report earnings?
  • Should I buy Cadrenal Therapeutics stock now?

What is the ticker symbol for Cadrenal Therapeutics?

The ticker symbol for Cadrenal Therapeutics is NASDAQ:CVKD

Does Cadrenal Therapeutics pay dividends?

No, Cadrenal Therapeutics does not pay dividends

What sector is Cadrenal Therapeutics in?

Cadrenal Therapeutics is in the Healthcare sector

What industry is Cadrenal Therapeutics in?

Cadrenal Therapeutics is in the Biotechnology industry

What country is Cadrenal Therapeutics based in?

Cadrenal Therapeutics is headquartered in United States

When did Cadrenal Therapeutics go public?

Cadrenal Therapeutics's initial public offering (IPO) was on January 20, 2023

Is Cadrenal Therapeutics in the S&P 500?

No, Cadrenal Therapeutics is not included in the S&P 500 index

Is Cadrenal Therapeutics in the NASDAQ 100?

No, Cadrenal Therapeutics is not included in the NASDAQ 100 index

Is Cadrenal Therapeutics in the Dow Jones?

No, Cadrenal Therapeutics is not included in the Dow Jones index

When was Cadrenal Therapeutics's last earnings report?

Cadrenal Therapeutics's most recent earnings report was on Mar 13, 2025

When does Cadrenal Therapeutics report earnings?

The next expected earnings date for Cadrenal Therapeutics is May 30, 2025

Should I buy Cadrenal Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page